Access without published appraisal: orphan medicine reimbursement and health equity in Türkiye
European Journal of Public Health · 09.10.2026 · 36 (6)
DOI: 10.1093/eurpub/ckag204 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Public Health, online erschienen am 04.11.2026. Verfasst von Ferit Sevim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare Management, Faculty of Health Sciences, Karadeniz Technical University, Trabzon, Türkiye. Hauptthemen laut MEDLINE: Orphan Drug Production, Rare Diseases, Health Equity, Health Services Accessibility. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific and Technological Research Council of Türkiye.
Abstract (Originalsprache)
Rare diseases are individually uncommon but collectively affect a substantial share of any population. The medicines developed for them combine severe conditions, very small treatable populations, high prices, and evidence that is often immature at launch. Conventional cost-effectiveness analysis handles this poorly, and systems relying on it heavily tend to reimburse fewer orphan medicines than those applying alternative evidence standards. Türkiye offers an instructive current case. Of the 66 orphan medicines granted central marketing authorization in the European Union between 2021 and 2024, 3 were available in Türkiye at the start of 2026, against a European Union average of 28. The comparable figure for all new medicines was 9 of 168, against an average of 76. Restricted access to orphan medicines should therefore not be read solely as an orphan-specific exclusion, but as part of a broader constraint on new medicines, distinguished by one feature: a parallel route in which medicines are authorized for named patients, imported, and reimbursed outside the standard list. That route carries real access that list-based indicators capture only in part, and it makes a patient entitlement depend on which list a medicine occupies. A rule issued in June 2026 restricting reimbursement of spinal muscular atrophy medicines after gene replacement therapy illustrates the limited public availability of the clinical and economic reasoning behind reimbursement restrictions. Broadening the basis of appraisal, rather than reducing reliance on economic evaluation, requires published criteria, instruments for managing uncertainty, and monitoring of the pathway as well as the list.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Healthcare Management, Faculty of Health Sciences, Karadeniz Technical University, Trabzon, Türkiye.
- Department of Healthcare Management, Graduate School of Health Sciences, Ankara University, Ankara, Türkiye.
- Department of Healthcare Management, Faculty of Health Sciences, Ankara University, Ankara, Türkiye.
ORCID-Profile: Ferit Sevim, Çağdaş Erkan Akyürek
Förderung
- Scientific and Technological Research Council of Türkiye
Zitieren
APA
Sevim, F., & Akyürek, Ç. E. (2026). Access without published appraisal: orphan medicine reimbursement and health equity in Türkiye. European Journal of Public Health, 36(6). https://doi.org/10.1093/eurpub/ckag204
Vancouver
Sevim F, Akyürek ÇE. Access without published appraisal: orphan medicine reimbursement and health equity in Türkiye. European Journal of Public Health. 2026;36(6). doi:10.1093/eurpub/ckag204
BibTeX
@article{Sevim2026,
author = {Sevim, Ferit and Akyürek, Çağdaş Erkan},
title = {Access without published appraisal: orphan medicine reimbursement and health equity in Türkiye},
journal = {European Journal of Public Health},
year = {2026},
volume = {36},
number = {6},
doi = {10.1093/eurpub/ckag204}
}
EUVIMED